Navigation Links
BioComp Pharma Launches First Generic Drug for Tindamax(R)
Date:2/3/2009

SAN ANTONIO, Feb. 3 /PRNewswire/ -- BioComp Pharma, Inc. launched Tinidazole 500, the first generic version of the FDA-approved drug Tindamax(R). Tindamax(R) is the only oral antimicrobial drug approved by the FDA for the treatment of both trichomoniasis (trich) and bacterial vaginosis (BV). BioComp Pharma will begin shipping the generic version of Tindamax(R) in February 2009.

Generic drugs have the same active ingredients and efficacy as branded drugs but, on average, cost 30 to 80 percent less.(1) In 2007, the average price of a generic prescription drug was $34.34, while the average price of a brand-name prescription drug was $119.41, according to the National Association of Chain Drug Stores.(2)

With an estimated 7.4 million new cases of trich in men and women each year,(3) it is the most common curable sexually transmitted disease in young, sexually-active women in the United States.(4) BV affects almost one-third of women (29.2 percent) in the United States(5) and is the most common vaginal infection in women of childbearing age.(6)

Tindamax(R) is administered in one gram (two 500 mg tablets, once daily for five days) or two grams (four 500 mg tablets, once daily for two days) for the treatment of BV, compared to the twice daily, seven day oral dosing of metronidazole, the current standard of care. Tindamax(R) is administered as two grams (four 500 mg tablets for one day) for the treatment of trich. The drug's formulation helps minimize treatment time by allowing for targeted dosing and a shorter course of therapy.

About BioComp Pharma, Inc.

BioComp Pharma, Inc. is a wholly-owned subsidiary of Mission Pharmacal Company, a privately-held pharmaceutical company based in San Antonio, Texas. Established in 2008, BioComp Pharma, Inc. distributes biocomparable drug products, which are less expensive than their prescription equivalent products. For more information on BioComp Pharma, visit www.biocomppharma.com.

About Tindamax(R)

Tindamax(R) is a second-generation 5-nitroimidazole compound and is indicated in the United States for the treatment of bacterial vaginosis, trichomoniasis, the intestinal infections giardiasis and intestinal amebiasis and amebic liver abscess.

    Media Contact:
    Cohn & Wolfe
    Ms. Ami Shah
    (212) 537-8048
    ami.shah@cohnwolfe.com

(1) Saving Money on Prescription Drugs. U.S. Food and Drug Administration. Accessed at:http://www.fda.gov/fdac/features/2005/505_save.html#generic. Last accessed: January 25, 2009

(2) Industry facts-at-a-glance. National Association of Chain Drug Stores. Accessed at: http://www.nacds.org/wmspage.cfm?parm1=507. Last accessed: January 25, 2009.

(3) Trichomoniasis - CDC Fact Sheet. Centers for Disease Control. Accessed at: http://www.cdc.gov/STD/Trichomonas/STDFact-Trichomoniasis.htm. Last accessed: January 24, 2009.

(4) Trichomoniasis - CDC Fact Sheet. Centers for Disease Control. Accessed at: http://www.cdc.gov/STD/Trichomonas/STDFact-Trichomoniasis.htm. Last accessed: January 24, 2009.

(5) J.E. Allsworth, J.F. Peipert. "Prevalence of Bacterial Vaginosis: 2001-2004 National Health and Nutrition Examination Survey Data," Obstetrics and Gynecology 2007; 109(1): 114-120.

(6) Bacterial Vaginosis - CDC Fact Sheet. Centers for Disease Control. Accessed at: http://www.cdc.gov/STD/BV/STDFact-Bacterial-Vaginosis.htm . Last accessed: 2009.


'/>"/>
SOURCE BioComp Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Osteotechs Plexur M(TM) Biocomposite Receives FDA Clearance in Spine
2. Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite
3. PharmaNet Development Group Agrees to be Acquired by JLL Partners
4. Chronic Lung Disease - Axentis Pharma Attracts Investment Interest
5. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
6. Quest PharmaTech Announces a Review of Strategic Alternatives to Enhance Shareholder Value
7. Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
8. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
9. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
10. SAFC Pharma Augments Assay Development Capabilities
11. Endo Pharmaceuticals to Announce Fourth Quarter and 2008 Full-Year Financial Results on February 27, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... ... 2016 , ... Shimadzu Scientific Instruments will showcase several new ... poster sessions, and present on the analysis of mycotoxins and medical cannabis at ... 10 at the Georgia World Congress Center in Atlanta, Georgia. , Attendees ...
(Date:2/4/2016)... SHENZHEN, China , Feb. 4, 2016 ... government, and various medical institutions attended a ceremony in ... provide integrative, personalized cell therapy in 2016. ... the "Shenzhen Clinical Translation Platform for Personalized Cell Therapy" ... Shenzhen Regional Cell Production Center, both subsidiaries of Beike ...
(Date:2/4/2016)... MENLO PARK, Calif. , Feb. 4, 2016   ... a biopharmaceutical company focused on the development and commercialization of ... the 18 th Annual BIO CEO & Investor ... EST in New York, NY . ... provide an update on the ongoing clinical trial of ...
(Date:2/4/2016)... EDISON, N.J. , Feb. 4, 2016 ... company focused on the development and commercialization of targeted ... BIO CEO & Investor Conference 2016, to be held ... and Source Capital Group,s 2016 Disruptive Growth & Healthcare ... on February 10-11, 2016. James Sapirstein ...
Breaking Biology Technology:
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... is apparently one of the most popular hubs ... Project, MetaHIT and other huge studies of human ... that past few years, the microbiome space has ... applied biomedical research. This report focuses on ...
(Date:2/3/2016)... --> --> ... Fingerprint Identification System Market by Component (Hardware and Software), ... Finance, Government, Healthcare, and Transportation) and Geography - Global ... expected to be worth USD 8.49 Billion by 2020 ... 2020. The transformation and technology evolution from the manual ...
(Date:2/3/2016)... , Feb. 3, 2016 ... the addition of the "Emotion Detection ... Machine Learning, and Others), Software Tools (Facial ... Areas, End Users,and Regions - Global forecast ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has ...
Breaking Biology News(10 mins):